GRAIL, LLC
1525 O'Brien Drive
Menlo Park
California
94025
United States
Tel: 833-694-2553
Website: https://grail.com/
Email: customerservice@grail.com
About GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.
LEADERSHIP:
CEO: Bob Ragusa
103 articles about GRAIL, LLC
-
GRAIL and Ochsner Health Launch New Initiatives to Improve Cancer Detection Rates in Louisiana
6/3/2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and Ochsner Health announced a multi-faceted partnership to improve cancer detection rates in Louisiana using Galleri®, GRAIL’s multi-cancer early detection blood test.
-
GRAIL Announces Strategic Collaboration With AstraZeneca to Develop Companion Diagnostic Tests to Enable the Treatment of Early-Stage Cancer
6/2/2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a broad strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca’s therapies.
-
GRAIL and Intermountain Healthcare Expand Partnership to Offer Galleri® Multi-Cancer Early Detection Blood Test to Eligible Patients in Utah
5/17/2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and Intermountain Healthcare announced that Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test, will be offered as a complement to existing single cancer screenings to help advance the delivery of cancer care through early detection.
-
The European Commission has provided an update that it remains unconvinced by the merger, which spells bad news for Illumina.
-
Such a deep, data-driven approach is enabling precision medicine, in particular, which is expanding from oncology to autoimmune diseases and other conditions.
-
GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test
12/6/2021
GRAIL, LLC announced today a partnership with Alignment Health Plan, a national Medicare Advantage health plan from Alignment Healthcare (NASDAQ: ALHC), to provide its Medicare Advantage members access to Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test.
-
Genomics veteran Bob Ragusa is taking over GRAIL, a newly-acquired business unit of Illumina, Inc. He is taking over as CEO Hans Bishop steps down from his role.
-
Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test Galleri
8/18/2021
Illumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers using Galleri test.
-
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
-
GRAIL Presents Interventional PATHFINDER Study Data at 2021 ASCO Annual Meeting and Introduces Galleri, a Groundbreaking Multi-Cancer Early Detection Blood Test
6/4/2021
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today presented the first results from the interventional PATHFINDER study evaluating Galleri™, a multi-cancer early detection
-
Cancer detection company GRAIL has entered into an agreement with Quest Diagnostics that sees Quest providing phlebotomy services to support GRAIL’s multi-cancer early detection blood test Galleri™.
-
GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test
1/11/2021
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today confirmed it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021. In December, GRAIL completed the enrollment of PATHFINDER, a prospective, 6,600-participant multi-si
-
GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease
1/11/2021
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced collaborations with global biopharmaceutical companies Amgen (NASDAQ:AMGN), AstraZeneca (LSE/STO/Nasdaq: AZN), and Bristol Myers Squibb (NYSE: BMY) to evaluate GRAIL’s methylation-based technology for the detection of minimal residual disease (MRD). Cancer MRD testing is used in clinical and research applications to detect
-
New Research Suggests Multi-Cancer Early Detection Blood Test Could Reduce Late-Stage Cancer Diagnoses by More Than Half
12/16/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today released new analyses estimating the potential of GRAIL’s multi-cancer early detection blood test to find more cancers earlier and save lives.
-
California-based Grail aims to alter the devastating trajectory of cancer mortality with the addition of one simple blood test.
-
GRAIL and UK Government to Make Galleri Multi-Cancer Early Detection Blood Test Available to Patients
11/27/2020
Agreement Aims to Help UK Meet its Goal of Diagnosing Three-Quarters of All Cancers at an Early Stage by 2028
-
Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC).
-
GRAIL Announces Filing of Registration Statement for Proposed Initial Public Offering
9/9/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock in the United States.
-
Amidst the pandemic, the biopharma industry continues to surge ahead. Jobs look plentiful. Check out these companies that have made recent job announcement expansions.
-
GRAIL to Present New Data Supporting its Multi-Cancer Early Detection Test at the American Association for Cancer Research (AACR) Annual Meeting II
6/22/2020
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced that new data for its investigational multi-cancer early detection blood test will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II. Today, the majority of deadly cancers go undetected until they have progressed to late stages, when chances of survival are much lower. This is bec